PPIA Peptide Biomarkers for Ovarian Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers for ovarian cancer, such as CA-125 and HE-4, often lead to unnecessary surgical interventions due to high false-positive rates, and there is a need for more effective methods to detect ovarian cancer at early stages.
Innovation Solution
The use of peptide fragments derived from the PPIA polypeptide, specifically the amino acid sequences VSFELFADK and FEDENFILK, as circulating biomarkers identified through mass spectrometry techniques, allowing for early detection of ovarian cancer in non-invasive blood samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional biomarkers (CA-125, HE-4) are used for ovarian cancer detection, then detection capability is provided, but false-positive rate increases leading to unnecessary surgical interventions
Solution Approach 1:
The invention segments the detection approach by using multiple specific peptide fragments (VSFELFADK and FEDENFILK from PPIA) instead of a single biomarker. This segmentation allows for more precise detection and reduces false positives by targeting specific cancer-related peptides rather than using broad conventional markers.
Solution Approach 2:
The invention changes the detection parameter from conventional biomarkers (CA-125, HE-4) to specific PPIA-derived peptide fragments. This parameter change enables more accurate detection of ovarian cancer at early stages while reducing the false-positive rate that leads to unnecessary surgical interventions.
2Reliability
If early stage ovarian cancer detection is achieved, then prognosis improves, but current methods lack sufficient sensitivity and specificity
Solution Approach 1:
The invention uses mass spectrometry as an intermediary technology to detect PPIA-derived peptide fragments in blood samples. This intermediary approach provides superior sensitivity and specificity for early-stage ovarian cancer detection compared to conventional biomarkers, enabling earlier intervention and improved prognosis.
Solution Approach 2:
The invention changes the detection parameter to specific PPIA peptide fragments (VSFELFADK and FEDENFILK) detected through mass spectrometry. This parameter change achieves the required measurement precision for early-stage detection, improving both sensitivity and specificity to enable better prognosis outcomes.
3Measurement precision
If mass spectrometry techniques are used to identify peptide biomarkers, then detection precision improves, but method complexity increases
Solution Approach 1:
The invention performs preliminary action by pre-identifying and validating specific PPIA-derived peptide fragments (VSFELFADK and FEDENFILK) as biomarkers. This preliminary work simplifies subsequent clinical testing, as the mass spectrometry method can be optimized for these specific peptides rather than requiring broad-spectrum biomarker discovery in each clinical setting.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the detection of ovarian cancer at earlier stages with higher specificity and sensitivity compared to conventional methods, reducing unnecessary interventions and improving prognosis.
Implementation Method 1
The use of peptide fragments derived from the PPIA polypeptide, specifically the amino acid sequences VSFELFADK and FEDENFILK, as circulating biomarkers identified through mass spectrometry techniques
Data Source
AI summary
This document provides methods and materials for identifying biomarkers (e.g., peptide biomarkers) that can be used to identify a mammal as having a disease (e.g., cancer). This document also provides methods and materials for identifying and/or treating cancer. For example, this document provides methods and materials for using one or more peptide fragments derived from a peptidyl-prolyl cis-trans isomerase A (PPIA) polypeptide to identify a mammal as having cancer (e.g., ovarian cancer).